MLTXMoonLake Immunotherapeutics
$10.83-80% 1Y
$10.83
$6.2452 weeks$61.99
MLTX as reported
- Net income
- −$264M
Net income · +50% year on year · trailing twelve months to Q2 2026
- Free cash flow
- −$225M
Free cash flow · +35% year on year · trailing twelve months to Q2 2026
- EPS
- −$3.84
EPS · +38% year on year · trailing twelve months to Q2 2026
Details›
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Net income | −$264M | +50% | Q2 2026 |
| EPS | −$3.84 | +38% | Q2 2026 |
| ROE | −78% | n/a | Q2 2026 |
| ROA | −54% | n/a | Q2 2026 |
| ROIC | 2219% | n/a | Q2 2026 |
| Free cash flow | −$225M | +35% | Q2 2026 |
Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.
MoonLake Immunotherapeutics (MLTX) · Net incomeNet incomeMoonLake Immunotherapeutics (MLTX)